SHANGHAI, Nov. 7, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 7, 2013.
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class C directors Dr. Ge Li and Stewart Hen, each to serve a three-year term.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com
Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com
SOURCE WuXi PharmaTech (Cayman) Inc.
Help employers find you! Check out all the jobs and post your resume.
